Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.Saccharomyces boulardii
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
A pooled reduction in antibiotic-associated diarrhea conflicts with a later large hospital trial, and rare invasive yeast infection is particularly relevant in vulnerable hosts.
Questions being reviewed
- In which antibiotic-treated populations does S. boulardii prevent clinically defined diarrhea?
- Does it prevent C. difficile-associated diarrhea or improve acute diarrhea consistently by age and setting?
- How should critical illness, central venous access, immunocompromise, and enteral feeding constrain use?
Immediate-release melatonin
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Immediate release can shift sleep onset more than total sleep in a direct pediatric trial, while pharmacokinetic differences alone do not establish better clinical sleep outcomes.
Questions being reviewed
- How much does immediate-release melatonin change sleep onset, total sleep, and waking time?
- When is rapid exposure useful, and when is an extended-release formulation the relevant comparator?
- Which pediatric findings generalize to adults, and what dose, duration, interaction, and product-quality limits apply?
Extended-release melatonin
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Prolonged exposure may target sleep maintenance, but small condition-specific trials conflict and pharmacokinetic plausibility is not equivalent to clinical efficacy.
Questions being reviewed
- Does extended-release melatonin improve maintained sleep and subjective sleep quality in a defined insomnia population?
- Which findings apply only to traumatic brain injury, Parkinson disease, autism, or other specific conditions?
- Do release profile, dose, timing, duration, and product quality change benefit or next-day effects?
Oat beta-glucan
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Oat beta-glucan has consistent modest LDL effects, but viscosity, molecular weight, food processing, dose, and the absence of event trials define the claim boundary.
Questions being reviewed
- How much does about 3–4 g/day of oat beta-glucan lower LDL, non-HDL cholesterol, and apoB?
- How do molecular weight, viscosity, processing, and food matrix change efficacy?
- Do lipid changes establish cardiovascular-event prevention, and what gastrointestinal effects affect adherence?
Glucomannan
- Review stage
- Extracting studies
- audited research papers
- 3
Why this is a research priority
Weight-loss claims exceed inconsistent short trials, constipation evidence is extremely small, and safe use depends on adequate water and separation from medicines.
Questions being reviewed
- Does glucomannan produce clinically meaningful, durable weight loss beyond lifestyle advice?
- Does it reliably improve constipation or metabolic markers in adequately controlled trials?
- How should water intake, swallowing difficulty, obstruction risk, and medicine timing constrain use?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.